Vivos Therapeutics, Inc. (VVOS): ANSOFF MATRIX [Dec-2025 Updated]

You're digging into Vivos Therapeutics, Inc. (VVOS) now, and frankly, the key to understanding their next move is their pivot to a direct-to-patient model, solidified by acquisitions like The Sleep Center of Nevada (SCN). This is a high-risk, high-reward strategy that's already showing traction, given they hit $2.2 million in diagnostic service revenue in Q3 2025. I've broken down their entire growth blueprint using the Ansoff Matrix, showing you the specific, concrete actions-from scaling up current patient throughput to exploring entirely new markets-that will define whether this aggressive strategy pays off for the company.

Vivos Therapeutics, Inc. (VVOS) - Ansoff Matrix: Market Penetration

You're looking at the immediate, existing market for Vivos Therapeutics, Inc. (VVOS) and how to sell more of what you already offer-the Vivos System and diagnostic services-to the current patient base, primarily through the Sleep Center of Nevada (SCN) and similar centers. This is about maximizing current capacity and reach.

Scale the Sleep Optimization (SO) teams to meet the demand backlog at SCN locations.

The urgency here is real because existing SO teams are experiencing multi-week backlogs. To address this, management projects deploying a total of 3.5 SO teams in Las Vegas by the end of 2025. Here's the quick math on what one team is expected to deliver: each fully operational SO team can process up to 250 patients monthly, potentially generating over $500,000 in monthly net collections with contribution margins above 50%. If onboarding takes 14+ days, churn risk rises.

The current capacity gap is significant. Vivos Therapeutics, Inc. believes it is currently servicing significantly less than 40% of the potential new patients being tested each month at SCN. This means the potential upside from scaling teams is substantial.

• Deploy 3.5 SO teams at SCN by year-end 2025.
• Target contribution margins above 50% per SO team.
• Address the existing multi-week backlog.

Increase patient throughput to maximize the $2.2 million Q3 2025 diagnostic service revenue.

The SCN acquisition is already showing its impact on the top line. For the third quarter of 2025, SCN added $2.2 million of diagnostic sleep testing revenue and $1.3 million of treatment center revenue. Total revenue for Q3 2025 hit $6.8 million, a 76% increase year-over-year. To build on this, throughput must increase to capture the remaining potential; remember, you are only servicing under 40% of the potential new SCN patients monthly. The legacy VIP Enrollment Revenue, which was $800,000 lower in Q3 2025, is expected to be fully recognized by the end of 2026, making the SCN throughput the primary driver.

Here is a snapshot of the Q3 2025 financial performance tied to these operations:

Aggressively target CPAP-intolerant patients with direct-to-consumer campaigns.

While specific direct-to-consumer (DTC) campaign spend or conversion data isn't immediately available, the market size is massive: OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed. The Vivos CARE oral medical devices are FDA-cleared for all severities of OSA in adults. The new CPT codes effective January 1, 2025, are designed to facilitate coverage and reimbursement by commercial medical insurance payers, which directly supports DTC conversion by lowering out-of-pocket costs.

Offer bundled pricing for the Vivos System and diagnostic services to boost unit sales.

The shift in revenue mix shows a move toward services, with Service Revenue increasing by an additional $2.7 million in Q3 2025, while Product Revenue saw only an approximate $200,000 increase. Bundling the Vivos System (product) with the diagnostic services that generated $2.2 million in Q3 2025 could drive higher overall transaction value and accelerate the adoption of the Vivos System itself. The company is exploring similar arrangements to the one in Michigan, which includes the full suite of Vivos treatments and services.

Secure in-network insurance contracts to lower patient out-of-pocket costs.

Management noted that getting more providers credentialed with insurance payors is a near-term focus to optimize SCN operations. The AMA issued new CPT codes applicable to all Vivos CARE oral medical devices, effective January 1, 2025, which is the mechanism to facilitate this coverage and reimbursement from commercial payers. Lowering the patient's cost is key to unlocking the market potential that the new codes enable.

Finance: draft 13-week cash view by Friday.

Vivos Therapeutics, Inc. (VVOS) - Ansoff Matrix: Market Development

Market Development for Vivos Therapeutics, Inc. (VVOS) centers on taking its existing, FDA-cleared technology into new geographic and distribution channels. This strategy is heavily anchored by the successful integration of the Sleep Center of Nevada (SCN) acquisition, which serves as the template for expansion.

Replicate the SCN acquisition model in new, high-density US markets like Michigan.

You're looking to scale the vertically integrated sleep center model that Vivos Therapeutics, Inc. established with the SCN acquisition in June 2025. SCN, which historically served over 200,000 Obstructive Sleep Apnea (OSA) patients since 2019, provided a large patient funnel. The financial impact of this model in the third quarter ended September 30, 2025, was significant, with SCN contributing $2.2 million in OSA sleep testing revenue and $1.3 million from treatment centers launched at its Las Vegas locations. This represented a 76% year-over-year revenue increase to $6.8 million for the quarter. Management projects having 3.5 Sleep Optimization (SO) teams operating at SCN by the end of 2025. The replication of this model is already underway in other markets. For instance, during the third quarter of 2025, Vivos Therapeutics, Inc. entered into a management agreement with MISleep Solutions LLC to offer its full suite of treatments at a joint location in Auburn Hills, Michigan, with patient appointments anticipated starting in early December. The SCN acquisition itself was valued at $8.7 million.

Form strategic alliances with major US hospital systems' sleep labs.

The SCN model itself is a form of strategic alliance/acquisition with a medical sleep practice, which management views as yielding a higher financial return compared to the legacy dentist-focused model. The company is actively looking to extend this model through contractual alliances or acquisitions of other medical sleep practices beyond the Las Vegas area. The shift away from the legacy business is evident as VIP enrollment revenue decreased by $800,000 in the third quarter of 2025 year-over-year, and management expects to finish recognizing this legacy revenue by the end of 2026.

Leverage the FDA-cleared pediatric device to build a national network of pediatric dentists.

Vivos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024 for its oral medical device to treat moderate to severe Obstructive Sleep Apnea (OSA) and snoring in children aged 6 to 17. This clearance is believed to be the first ever for an oral medical device for this indication. The potential market is substantial, with an estimated 10.1 million U.S. children in that age range suffering from pediatric OSA. To facilitate broader adoption and reimbursement, new American Medical Association (AMA) CPT codes for all Vivos CARE oral medical devices are set to take effect on January 1, 2025.

• FDA 510(k) clearance received: September 2024.
• Target pediatric age group: 6 to 17.
• New CPT codes effective: January 1, 2025.
• Estimated U.S. pediatric OSA patients: 10.1 million.

Pursue regulatory clearance in key international markets, starting with Canada or the UK.

While the company has noted that its FDA clearance is the latest in a series of regulatory wins globally, specific, current 2025 financial or operational milestones regarding active pursuit of regulatory clearance in Canada or the UK were not detailed in the latest earnings reports. Historically, the company acknowledged the requirement to obtain clearance from international regulatory bodies before marketing products abroad.

Establish a defintely scalable, low-cost remote diagnostic service for rural areas.

The current focus on scaling the sleep center model, which includes diagnostic testing, suggests a path toward increased service capacity. The company's overall strategy is to place its technology in front of far more OSA patients. However, specific financial figures or pilot program results related to a dedicated, low-cost remote diagnostic service targeting rural areas were not provided in the Q3 2025 data.

Finance: draft 13-week cash view by Friday.

Vivos Therapeutics, Inc. (VVOS) - Ansoff Matrix: Product Development

You're looking at Vivos Therapeutics, Inc.'s (VVOS) strategy for growing its product offerings, which is the Product Development quadrant of the Ansoff Matrix. This involves enhancing existing core technology and expanding into adjacent therapeutic areas.

A key enabler for the current product line, the Complete Airway Repositioning and Expansion (C.A.R.E.) devices, is the new reimbursement structure. The American Medical Association issued new Current Procedural Terminology (CPT) coverage and reimbursement codes applicable to all Vivos CARE oral medical devices, which became effective on January 1, 2025. This regulatory step directly supports the commercial viability of the existing devices and any next-generation iterations, such as one with enhanced comfort features.

The financial results for the nine months ended September 30, 2025, show the company generated USD 13.62 million in revenue, a 20% increase compared to the same period in 2024. Product revenue specifically saw an 8% year-over-year increase in the first quarter of 2025, with the company selling 3,736 oral appliance arches for approximately $1.8 million during that quarter. This revenue stream is what funds the development of future products.

The strategic pivot toward sleep medical practice acquisition, highlighted by the June 10, 2025, acquisition of The Sleep Center of Nevada (SCN), directly relates to integrating proprietary home sleep testing (HST) technology. The service revenue from SCN, which includes sleep testing services, contributed an additional $2.7 million in Q3 2025 alone. This operational shift is intended to capture diagnostic revenue, which is a necessary precursor to deploying the Vivos Method protocol that would incorporate integrated HST.

The development of a post-treatment retention appliance line is aimed squarely at creating a recurring revenue stream, moving away from the legacy model. Management has stated they are expecting to be finished with recognizing any such legacy revenue by the end of 2026, making the development of new, recurring revenue sources like retention appliances critical for the near term.

While specific revenue figures for a new software platform or a non-OSA appliance are not yet public, the company did note that for the three months ended September 30, 2025, there was an increase in revenue from software and medical reporting services. The ongoing net loss for the nine months ended September 30, 2025, stood at $14.28 million, underscoring the investment required for these product expansion efforts, especially given that cash and cash equivalents were only $3.1 million against total liabilities of $23.1 million as of September 30, 2025.

Here's a quick look at the reported financial performance that underpins the investment in these product developments:

The expansion into new indications, such as a non-OSA oral appliance for chronic headaches or migraines, leverages the existing FDA clearances for the C.A.R.E. devices, which are the only oral appliances cleared by the FDA for treating severe Obstructive Sleep Apnea (OSA) in adults and moderate to severe OSA in children ages 6 to 17.

The company's focus areas for product development are:

• Launch next-generation C.A.R.E. device with enhanced comfort.
• Integrate proprietary home sleep testing into the Vivos Method.
• Develop a post-treatment retention appliance line.
• Commercialize a new provider software platform.
• Introduce a non-OSA oral appliance for headaches/migraines.

The transition to the sleep center model, which saw SCN generate approximately $500,000 in service revenue in just twenty days following its June 10, 2025 closing, is the vehicle for commercializing diagnostic and tracking tools like the new software platform.

Finance: draft 13-week cash view by Friday.

Vivos Therapeutics, Inc. (VVOS) - Ansoff Matrix: Diversification

You're looking at growth beyond the core business, which is smart, especially given Vivos Therapeutics, Inc.'s current financial footing. The nine months ended September 30, 2025, showed revenue climbing to $13.6 million, up from $11.3 million a year prior, but the net loss also widened to $14.3 million. Cash on hand sits at just $3.1 million against total liabilities of $23.1 million as of that date, which definitely puts a spotlight on the need for new, scalable revenue streams outside the legacy VIP enrollment model that management expects to phase out by the end of 2026.

Acquire a complementary medical device company focused on non-OSA respiratory health, like asthma.

Moving into adjacent respiratory health, like asthma devices, taps into a large, established market. The global COPD and Asthma Drug Devices Market size was over $50.3 billion in 2025. Specifically, the global Metered Dose Inhalers Market size is projected to be $18,251.6 million in 2025. Acquiring a company here means integrating a product line into a market segment where North America already accounts for a major share, over 40% of the global revenue for MDIs in 2025. This is a product development play within a related market space, effectively a form of diversification.

Develop a proprietary non-pharmaceutical treatment for Temporomandibular Joint Disorder (TMD), leveraging existing dental channels.

This strategy leans into the existing dental channel expertise but targets a different condition. The global TMJ Disorders Market size was expected to be $614.11 million in 2025, growing from $588.34 Million in 2024. If you look at the TMJ Implants segment alone, its market size is projected at $5.6 billion in 2025. Developing a non-pharmaceutical treatment offers a proprietary angle, which is key when the overall TMD market is fragmented and medication currently generates the highest revenue share, about 53.3% of total market revenue in one analysis. The fact that TMD affects up to 15% of adults, according to the American Family Physician, shows a significant patient pool to target.

Enter the general sleep wellness market with a consumer-grade, non-medical sleep tracking wearable.

This is a move into a high-growth, consumer-facing market, distinct from Vivos Therapeutics, Inc.'s current medical device focus. The broader Sleep Tech Devices Market is estimated at $23.32 Billion in 2025. Within that, the segment for wearable sleep trackers is projected to be $22.5 billion by 2025, with an anticipated Compound Annual Growth Rate (CAGR) of around 18% through 2033. The wearables segment already holds the largest share of the sleep tech market, estimated at 55.3% in 2025. North America dominates this space, holding a market share of 39.8% in 2025.

Partner with a major US telehealth provider to offer virtual consultations for a broader range of sleep disorders.

Partnering leverages existing infrastructure to expand service reach without immediate capital expenditure on new physical centers. The U.S. Telehealth Market size is projected to reach $94.3 billion in 2025. The services component of this market dominated in 2023 at $35.1 billion. For Vivos Therapeutics, Inc., this means scaling its diagnostic and treatment consultation capacity-a service that aligns with its recent pivot, which saw service revenue growth driven by the June 2025 acquisition of The Sleep Center of Nevada for $8.7 million. The company's Q3 2025 revenue of $6.8 million was significantly boosted by service revenue, showing the immediate impact of this channel.

Establish a specialized clinic model focused on the link between airway health and pediatric ADHD, based on recent clinical data.

This targets a specific comorbidity niche within a large, growing therapeutic area. The global ADHD Therapeutics Market size was projected to be $38.37 billion in 2025. In the U.S. specifically, the market was valued at $10.31 billion in 2024. Focusing on the pediatric aspect, the U.S. Pediatric Healthcare Market size was projected to be $4.18 billion in 2024. Establishing clinics for this focus area would place Vivos Therapeutics, Inc. in a segment where the global market is expected to grow at a CAGR of 9.09% from 2025 to 2033. The hospital pharmacy segment within ADHD therapeutics is projected to grow fastest at a CAGR of 8.7% from 2025 to 2033, indicating a strong clinical pathway for new diagnostic/treatment centers.

Here's a quick look at Vivos Therapeutics, Inc.'s recent financial position and the market scale for these diversification targets:

The pivot to a sleep-center driven model is showing initial traction, with Q3 2025 revenue reaching $6.8 million, a 76% year-over-year increase, largely due to the SCN acquisition. However, operating expenses rose to $21.1 million for the nine months, leading to the significant cash burn of $11.5 million year-to-date. The company secured $14.2 million in net cash from financing activities to support this expansion.

Potential areas for synergistic growth through diversification include:

• Expanding the non-OSA respiratory device portfolio to capture a share of the $50.3 billion market.
• Developing proprietary TMD solutions to address a market segment valued at over $600 million in 2025.
• Entering the consumer wellness space, where wearables represent a 55.3% share of a $23.32 billion market in 2025.
• Scaling service delivery via telehealth partnerships, tapping into a $94.3 billion US market in 2025.
• Creating specialized pediatric clinics targeting the intersection of airway health and ADHD within a global therapeutics market worth $38.37 billion in 2025.

The current gross margin for Vivos Therapeutics, Inc. is 55% for the nine months of 2025, down from 61% in the comparable 2024 period, which highlights the need for diversification that can bring higher-margin or more stable revenue streams. Finance: draft 13-week cash view by Friday.